Literature DB >> 32763241

Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.

Mazen Noureddin1, Calum Jones2, Naim Alkhouri3, Eduardo Vilar Gomez4, Douglas T Dieterich5, Mary E Rinella6.   

Abstract

Entities:  

Keywords:  Cirrhosis; Fibrosis; High-risk population; NASH; Screening

Mesh：

Year:  2020        PMID： 32763241     DOI： 10.1053/j.gastro.2020.07.050

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  22 in total

Review 1.  Defining comprehensive models of care for NAFLD.

Authors:  Manuel Romero-Gómez; Jörn M Schattenberg; Jeffrey V Lazarus; Quentin M Anstee; Hannes Hagström; Kenneth Cusi; Helena Cortez-Pinto; Henry E Mark; Michael Roden; Emmanuel A Tsochatzis; Vincent Wai-Sun Wong; Zobair M Younossi; Shira Zelber-Sagi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-25       Impact factor: 46.802

2.  AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.

Authors:  Michelle T Long; Mazen Noureddin; Joseph K Lim
Journal:  Gastroenterology       Date:  2022-07-14       Impact factor: 33.883

Review 3.  Using Telehealth for Diagnosis and Management of Non-Alcoholic Fatty Liver Disease.

Authors:  Hamid-Reza Moein; Elvis J Arteaga; Souvik Sarkar
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-04-29

Review 4.  Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jay H Shubrook; Leon A Adams; Kim Pfotenhauer; Vincent Wai-Sun Wong; Eugene Wright; Manal F Abdelmalek; Stephen A Harrison; Rohit Loomba; Christos S Mantzoros; Elisabetta Bugianesi; Robert H Eckel; Lee M Kaplan; Hashem B El-Serag; Kenneth Cusi
Journal:  Gastroenterology       Date:  2021-09-20       Impact factor: 33.883

5.  Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes.

Authors:  Hiroshi Ishiba; Yoshio Sumida; Yuya Seko; Saiyu Tanaka; Masato Yoneda; Hideyuki Hyogo; Masafumi Ono; Hideki Fujii; Yuichiro Eguchi; Yasuaki Suzuki; Masashi Yoneda; Hirokazu Takahashi; Takashi Nakahara; Kojiro Mori; Kazuyuki Kanemasa; Keiji Shimada; Kento Imajo; Kanji Yamaguchi; Takumi Kawaguchi; Atsushi Nakajima; Kazuaki Chayama; Toshihide Shima; Kazuma Fujimoto; Takeshi Okanoue; Yoshito Itoh
Journal:  Hepatol Commun       Date:  2020-11-16

6.  Nonalcoholic fatty liver disease-related hepatocellular carcinoma growth rates and their clinical outcomes.

Authors:  Jihane N Benhammou; Jonathan Lin; Elizabeth S Aby; Daniela Markovic; Steven S Raman; David S Lu; Myron J Tong
Journal:  Hepatoma Res       Date:  2021-11-05

Review 7.  What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?

Authors:  Naim Alkhouri; Monica Tincopa; Rohit Loomba; Stephen A Harrison
Journal:  Hepatol Commun       Date:  2021-09-09

Review 8.  Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.

Authors:  Daniel Ferguson; Brian N Finck
Journal:  Nat Rev Endocrinol       Date:  2021-06-15       Impact factor: 43.330

9.  An Algorithmic Approach to NAFLD Screening: From PCP to Specialist.

Authors:  Hirsh D Trivedi
Journal:  ACG Case Rep J       Date:  2020-11-11

10.  Changing trends in liver transplantation indications in Saudi Arabia: from hepatitis C virus infection to nonalcoholic fatty liver disease.

Authors:  Saleh A Alqahtani; Dieter C Broering; Saad A Alghamdi; Khalid I Bzeizi; Noara Alhusseini; Saleh I Alabbad; Ali Albenmousa; Nasreen Alfaris; Faisal Abaalkhail; Waleed K Al-Hamoudi
Journal:  BMC Gastroenterol       Date:  2021-06-01       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.